These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Brechtel B; Haas N; Henz BM; Kolde G Br J Dermatol; 1996 Aug; 135(2):307-9. PubMed ID: 8881681 [TBL] [Abstract][Full Text] [Related]
25. Drug survival of thalidomide for dermatological conditions: A single-centre review. Arasu A; Lee S; Chian Yeoh A; Ross G Australas J Dermatol; 2021 Feb; 62(1):e107-e109. PubMed ID: 32627846 [No Abstract] [Full Text] [Related]
30. Thalidomide for dermatology: a review of clinical uses and adverse effects. Faver IR; Guerra SG; Su WP; el-Azhary R Int J Dermatol; 2005 Jan; 44(1):61-7. PubMed ID: 15663665 [No Abstract] [Full Text] [Related]
31. A case of childhood sarcoidosis. Hunt SJ; O'toole E; Philips W; Hardman C; Wakelin SH; Walters S Clin Exp Dermatol; 2002 Sep; 27(6):448-50. PubMed ID: 12372081 [TBL] [Abstract][Full Text] [Related]
32. [Methotrexate for the treatment of patients with chronic cutaneous sarcoidosis: 4 cases]. Gary A; Modeste AB; Richard C; Jubert C; Majour F; Nouvet G; Remond B; Joly P Ann Dermatol Venereol; 2005; 132(8-9 Pt 1):659-62. PubMed ID: 16230915 [TBL] [Abstract][Full Text] [Related]
33. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. Sené T; Juillard C; Rybojad M; Cordoliani F; Lebbé C; Morel P; Tazi A; Guibal F J Am Acad Dermatol; 2012 Feb; 66(2):328-32. PubMed ID: 22243729 [No Abstract] [Full Text] [Related]
34. Thalidomide in leprosy and some dermatological conditions--a review. Parikh DA; Maniar JK; Ganapati R Indian J Lepr; 1985; 57(4):862-7. PubMed ID: 3915010 [No Abstract] [Full Text] [Related]
35. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Baughman RP; Judson MA; Ingledue R; Craft NL; Lower EE Arch Dermatol; 2012 Feb; 148(2):262-4. PubMed ID: 22004880 [No Abstract] [Full Text] [Related]